Brokerages predict that Soligenix, Inc. (NASDAQ:SNGX) will announce earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Soligenix’s earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.22). Soligenix posted earnings of ($0.17) per share in the same quarter last year, which would indicate a negative year over year growth rate of 88.2%. The business is scheduled to report its next earnings report on Monday, March 26th.
On average, analysts expect that Soligenix will report full-year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($1.10). For the next year, analysts expect that the firm will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.49) to ($1.13). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Soligenix.
A number of analysts recently issued reports on SNGX shares. Maxim Group set a $5.00 price objective on Soligenix and gave the stock a “buy” rating in a report on Thursday, December 21st. HC Wainwright cut Soligenix from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $5.50 to $2.70 in a report on Wednesday, January 31st.
COPYRIGHT VIOLATION NOTICE: “-$0.32 EPS Expected for Soligenix, Inc. (SNGX) This Quarter” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3299001/0-32-eps-expected-for-soligenix-inc-sngx-this-quarter.html.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.